Baxter (NYSE:BAX) today announced the global launch of its PrisMax 2, meant to simplify the delivery of continuous renal replacement therapy (CRRT) and other organ support therapies.
The next-gen PrisMax 2 system includes new features from the company’s TrueVue digital health portfolio. There’s also the PrismaLung+ blood-gas exchanger that delivers extracorporeal carbon dioxide removal therapy for ICU patients with acute respiratory dysfunction.
Baxter plans to have PrisMax 2 and TrueVue available soon in more than 20 countries across the United States and Europe. PrismaLung+ is available in select markets in western Europe, but it is not presently cleared or approved in the U.S.
“Baxter is committed to partnering with healthcare professionals to foster continuous innovation in the ICU, which has been particularly critical throughout the COVID-19 pandemic,” said Reaz Rasul, GM of Baxter’s Acute Therapies business, in a news release.
“We are proud to provide industry-leading technologies and services through our PrisMax 2 system to help expand treatment possibilities by making CRRT and other extracorporeal organ support therapies more accessible, Rasul said.